ClinicalTrials.gg
RecruitingNCT07304661Updated Nov 4, 2026

Comparison of PPV and LVOT VTI During Passive Leg Raising to Predict Fluid Responsiveness

An observational study in Hemodynamic Instability, Hypovolemia and Critical Illness, sponsored by Izmir Katip Celebi University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Izmir Katip Celebi University · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 4, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
48
Ages
18 Years and older
Sex
All
01

Study summary

Hemodynamic instability remains one of the leading causes of morbidity and mortality among critically ill patients in intensive care units. One major contributor to this instability is intravascular fluid deficit. Although fluid administration is often preferred as an initial intervention, inaccurate estimation of fluid requirements carries significant risks. Inadequate resuscitation may lead to tissue hypoperfusion and organ dysfunction, whereas excessive fluid loading is associated with pulmonary edema, increased intra-abdominal pressure, multi-organ dysfunction, and increased mortality. Consequently, reliable prediction of fluid responsiveness is considered a critical determinant in modern intensive care management.

The limited reliability of static parameters in predicting fluid responsiveness and the fact that PPV retains its validity only under specific clinical conditions highlight the need for more effective methods. In recent years, hemodynamic changes assessed during the passive leg raising (PLR) maneuver have gained prominence; particularly, left ventricular outflow tract velocity time integral (LVOT VTI)-based cardiac output measurements have been identified as a strong parameter for predicting fluid responsiveness . Moreover, changes in pulse pressure variation (PPV) during PLR have also been reported as a potential predictor; however, the number of studies prospectively comparing PPV variation and LVOT VTI-based cardiac output change within the same patient population remains limited . Therefore, the proposed study aims to fill this gap in the literature and contribute to fluid management in the intensive care setting.

The aim of this study is to compare the performance of PPV variation and LVOT VTI-based cardiac output change after the PLR maneuver in predicting fluid responsiveness among mechanically ventilated critically ill patients, and to determine the diagnostic value of both methods. The findings of the present study are expected to support more reliable decision-making in fluid therapy and provide clinical evidence toward the individualization of fluid management in intensive care practice.

Read the detailed description

This study is designed as a prospective observational trial. No additional intervention, procedure, or treatment beyond standard clinical practice will be performed. All data will be obtained during routine clinical management in our intensive care unit.

In mechanically ventilated patients with suspected fluid deficit, the passive leg raising (PLR) maneuver is applied as part of standard practice, during which changes in pulse pressure variation (PPV) are recorded by invasive arterial monitoring.

In this observational study, transthoracic echocardiographic (TTE) measurements of LVOT VTI will be performed by an experienced operator in addition to routine practice. Using pulse wave Doppler (PW), LVOT VTI will be recorded, and stroke volume (SV) and cardiac output (CO) will be calculated by multiplying the LVOT VTI value by the LVOT diameter. Consequently, changes in PPV and LVOT VTI-based CO during PLR will be compared.

Following TTE measurements of LVOT VTI and LVOT diameter in both the semi-recumbent position (45°) and immediately after PLR, SV and CO will be calculated. Based on these measurements, patients will be allocated into two groups:

  • Fluid responsive: Patients showing ≥10% increase in LVOT VTI-based CO following PLR
  • Non-fluid responsive: Patients showing \<10% change in LVOT VTI-based CO following PLR

After grouping patients accordingly, PPV changes during PLR will be compared between the two groups. This will allow evaluation of the predictive performance of PPV variation relative to LVOT VTI-based CO change in determining fluid responsiveness. All measurements will be performed by an experienced clinician without disrupting standard patient care. No additional fluid loading, invasive procedures, or therapeutic interventions will be undertaken throughout the study.

The primary aim is to compare the diagnostic performance of PPV variation and LVOT VTI-based cardiac output changes following a PLR maneuver in predicting fluid responsiveness. The study seeks to determine the diagnostic value of both methods to support more individualised fluid management.

The recorded data will include:

  • Pre- and post-PLR LVOT VTI, stroke volume, cardiac output, and PPV values
  • Routine monitoring parameters (systolic/diastolic blood pressure, mean arterial pressure, heart rate, and SpO₂)
  • Demographic characteristics (age, sex, comorbidities) retrieved through the hospital database

Informed consent will be obtained from all participating patients or their legally authorized representatives.

02

Conditions studied

  • Hemodynamic Instability
  • Hypovolemia
  • Critical Illness
  • Pulse Pressure Variation

Keywords

  • Fluid Responsiveness
  • Passive Leg Raising
  • Pulse Pressure Variation
  • LVOT VTI
  • Cardiac Output
  • Echocardiography
03

In context

Hypovolemia

122 studies on the registry are indexed under Hypovolemia; 14 are open to participants now.

This study's planned enrollment of 48 is close to the median of 51 across 58 observational studies indexed under Hypovolemia.

Browse Hypovolemia studies →

Lead sponsor

Izmir Katip Celebi University is the lead sponsor of 198 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult critically ill patients admitted to the Intensive Care Unit (ICU) who are receiving mechanical ventilation support. Eligible participants are those identified by the intensive care team as having a suspected intravascular fluid deficit, for whom a fluid responsiveness assessment is clinically indicated. The cohort specifically targets patients undergoing the Passive Leg Raising (PLR) maneuver as part of routine standard practice, where invasive arterial monitoring is available to record Pulse Pressure Variation (PPV).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients aged ≥18 years
  2. Patients admitted to the intensive care unit receiving mechanical ventilation
  3. Presence of suspected intravascular fluid deficit (hypotension, negative fluid balance, or clinical signs of peripheral hypoperfusion)
  4. Patients in sinus rhythm
  5. Presence of invasive arterial blood pressure monitoring
  6. Adequate echocardiographic window allowing transthoracic echocardiographic measurement of LVOT VTI
  7. Patients ventilated with tidal volume ≥8 mL/kg (ideal body weight)
  8. Hemodynamically stable enough to allow measurement

Exclusion criteria

Exclusion Criteria:

  1. Patients under 18 years of age
  2. Presence of atrial fibrillation or significant arrhythmias such as frequent ventricular or atrial ectopy
  3. Severe right ventricular dysfunction or significant tricuspid regurgitation
  4. Advanced aortic valve disease (severe stenosis or severe regurgitation)
  5. Patients with significant spontaneous breathing effort
  6. Patients receiving lung-protective low tidal volume ventilation strategy (\<8 mL/kg) due to ARDS
  7. Inadequate echocardiographic window for LVOT VTI assessment
  8. Severe hemodynamic instability during measurement (sudden vasopressor escalation or need for resuscitation)
  9. Patients who refuse to participate or from whom written cannot be obtained from themselves or a first-degree relative
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
48 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Fluid Responders

    Defined as an increase in LVOT VTI-based Cardiac Output (CO) of ≥ 10% from baseline.

  • Fluid Non-Responders

    Defined as an increase in LVOT VTI-based Cardiac Output (CO) of \< 10% from baseline.

06

What researchers measure

Primary outcomes

  1. Change in Pulse Pressure Variation (Delta PPV)

    Pulse Pressure Variation (PPV) is recorded via invasive arterial monitoring at baseline (T0, semi-sitting) and during the Passive Leg Raising maneuver (T1).

    Time frame: Baseline (T0) and between 60 seconds after the PLR maneuver.

Secondary outcomes

  1. Percentage Change in Cardiac Output (Delta CO)

    Cardiac Output (CO) is calculated using the Left Ventricular Outflow Tract Velocity Time Integral (LVOT VTI) and the LVOT diameter measured via transthoracic echocardiography.

    Time frame: Baseline (T0) and between 60 seconds after the PLR maneuver.

  2. Correlation between Delta PPV and Delta CO

    Correlation Coefficient (r) between PPV Change and Cardiac Output Change

    Time frame: Baseline (T0) and between 60 seconds after the PLR maneuver.

  3. Hemodynamic Parameter Changes (MAP, HR)

    Measurement of changes in mean arterial pressure and heart rate before and after PLR and comparison between groups.

    Time frame: Baseline (T0) and between 60 seconds after the PLR maneuver.

  4. Diagnostic Accuracy (ROC-AUC, Sensitivity, Specificity, Cut-off)

    Evaluation of diagnostic performance of ΔPPV and ΔCO using receiver operating characteristic (ROC) analysis, including AUC, optimal cut-off value, sensitivity, and specificity for predicting fluid responsiveness.

    Time frame: Baseline (T0) and between 60 seconds after the PLR maneuver.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — All data necessary to support the study protocol, including de-identified individual participant data (IPD) related to study protocol, and primary and secondary outcome measures, will be made available upon reasonable request from qualified researchers for academic purposes, in accordance with institutional and ethical guidelines.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

Of 25 observational studies under Hypovolemia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2025
First posted
Dec 26, 2025
StartActual
Jan 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
Izmir Katip Celebi University Atatürk Training and Research Hospital İzmir, , Turkey is now Recruiting
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    Izmir Katip Celebi University Atatürk Training and Research Hospital İzmir, , Turkey is now Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07304661
Responsible party
Ahmet Salih Tüzen, MD (Medical Doctor, Izmir Katip Celebi University) — Principal investigator
First posted
Dec 26, 2025
Start date
Jan 1, 2026
Primary completion
Jan 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Murat Aksun, M.D.
Contact
murataksun@yahoo.com
+90 552 363 16 14
Ahmet Salih Tüzen, M.D.
Contact
astuzen@icloud.com
+90 535 391 55 77
Murat Aksun
principal investigator · Izmir Katip Celebi University Atatürk Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion